David L. Ramirez, MD
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Medical Director, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Quality Officer, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2003 | Boston University School of Medicine, Boston, Massachusetts, US, MD |
| 1999 | University of Texas at El Paso, El Paso, Texas, US, Bachelor of Science, BS |
Postgraduate Training
| 2009-2012 | Clinical Fellowship, University of California Davis Cancer Center, Sacramento, California |
| 2006-2009 | Clinical Residency, University of Texas Health Science Center, Houston, Texas |
Board Certifications
| 2009 | Hematology |
| 2009 | Oncology |
| 2006 | Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Assistant Professor, Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX, 2014 - 2015
Attending Faculty in Oncology Clinic, Harris County Hospital District, Lyndon B. Johnson General Hospital, Houston, TX, 2012 - 2015
Assistant Professor, Department of General Oncology, Harris Health Systems/Lyndon B. Johnson General Hospital, Houston, TX, 2012 - 2015
Administrative Appointments/Responsibilities
Associate Medical Director, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Department Quality Officer, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Fellowship Steering Committee, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Educational/CME Director, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Fellowship Steering Committee Member, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Breast Surgical Oncology Fellowship Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Other Appointments/Responsibilities
Clinical Oncologist/Hematologist, Kaiser Permanente, Vacaville, CA, 2009 - 2012
Institutional Committee Activities
Member, Credentials Committee of the Medical Staff (CCMS),, 2020 - Present
Member, Pharmacy and Therapeutics Committee, 2019 - Present
Co-Chair, Breast Multidisciplinary Tumor Board, LBJ General Hospital, 2013 - Present
Member, Fellowship Steering Committee Member, 2012 - Present
Honors & Awards
| 2024 | Division of Cancer Medicine Teaching Department of the Year, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2024 | Division of Cancer Medicine Leadership in Education Award, The University of Texas MD Anderson Cancer Center Hematology/Oncology Fellowship Program |
| 2024 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2023 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2023 | Division of Cancer Medicine Teaching Department of the Year, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2023 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2022 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2022 | President's recognition of faculty excellence–education and mentorship advancement, The University of Texas MD Anderson Cancer Center |
| 2022 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2021 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2021 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2020 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2020 | Division of Cancer Medicine Educator of the Year, The University of Texas MD Anderson Cancer Center |
| 2020 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2019 | Division of Cancer Medicine Teacher of the Year Award, The University of Texas MD Anderson Cancer Center Hematology/Medical Oncology Fellowship Program |
| 2019 | Multidisciplinary Educator of the Year, Breast Surgical Oncology Fellowship Program The University of Texas MD Anderson Cancer Center |
| 2015 | Vicente Valero LBJ Clinical Educator of the Year Award, The University of Texas MD Anderson Cancer Center |
| 2013 | Fellow's Teaching Award, The University of Texas MD Anderson Cancer Center |
| 2013 | Vicente Valero LBJ Clinical Educator of the Year Award, The University of Texas MD Anderson Cancer Center |
| 2013 | Division of Cancer Medicine Educator of the Year, The University of Texas MD Anderson Cancer Center |
| 2003 | Massachusetts Medical Society Scholar |
| 2003 | Ruth Batson Academic Medical Scholarship |
| 2002 | Ruth Batson Academic Medical Scholarship |
| 2002 | Massachusetts Medical Society Scholar |
| 2001 | Ruth Batson Academic Medical Scholarship |
| 2001 | Massachusetts Medical Society Scholar |
| 2000 | Ruth Batson Academic Medical Scholarship |
| 2000 | Massachusetts Medical Society Scholar |
| 1999 | Massachusetts Medical Society Scholar |
| 1999 | Ruth Batson Academic Medical Scholarship |
| 1999 | Dean's List at the University of Texas at El Paso |
| 1998 | Dean's List at the University of Texas at El Paso |
| 1997 | Dean's List at the University of Texas at El Paso |
| 1997 | Who's Who - Collegiate Scholars |
| 1997 | Alpha Lambda Delta |
| 1997 | Alpha Epsilon Delta |
| 1996 | All-American Scholar Collegiate Award |
| 1996 | Dean's List at the University of Texas at El Paso |
| 1996 | Golden Key National Honor Society |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res 30(11):2424-2432, 2024. PMID: 38629963.
- Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez DL, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
- Lopez G, Eng C, Overman M, Ramirez DL, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen L. Publisher Correction: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep 13(1):8318, 2023. e-Pub 2023. PMID: 37221249.
- Lopez G, Eng C, Overman M, Ramirez DL, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen L. A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep 12(1):19023, 2022. e-Pub 2022. PMID: 36348045.
- Yam, C, Rauch, GM, Rahman, T, Karuturi, MS, Ravenberg, EE, White, JB, Clayborn, A, McCarthy, P, Abouharb, S, Lim, B, Litton, J, Ramirez, DL, Saleem, S, Stec, J, Symmans, WF, Huo, L, Damodaran, S, Sun, R, Moulder, S. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs 39(2):509-515, 2021. PMID: 32984932.
- Gibson G, Ramirez DL, Maier J, Castillo C, Das S. Giardia lamblia: Incorporationof free and conjugated fatty acids into glycerol-based phospholipids. Experimental Parasitology 92(1): 1-11, 1999. PMID: None.
Abstracts
- Klein K, Park Hwang J, Valero V, Ramirez DL, Kaushik J. Viral hepatitis screening in patients with early breast cancer receiving cancer therapy: A quality improvement initiative. 2024 ASCO Annual Meeting 42(16), 2024. PMID: None.
- Iwase T, Alexander A, Cohen EN, Gao H, Chiv VY, Kai M, Kida K, Krishnamurthy S, Liu D, Shen Y, Ramirez DL, Reuben A, Tripathy D, Booser DJ, Moulder, SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer. 2023 ASCO Annual Meeting 41(16), 2023. PMID: None.
- Singareeka Raghavendra A, Kwiatkowski D, Damodaran S, Kettner NM, Ramirez DL, Gombos DS, Hunt K, Shen Y, Keyomarsi K, Tripathy D. Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC). 2021 ASCO Annual Meeting 39(15), 2021. PMID: None.
- Lopez G, Eng C, Overman MJ, Liu W, Cohen L, Ramirez DL, Beinhorn CM, Sumler PA, Chen M, Bruera E, Prinsloo S, Li Y. A Pilot Study of Oncology Massage to treat Chemotherapy-Induced Peripheral Neuropathy (CIPN). 2019 ASCO Annual Meeting 37(15), 2019. PMID: None.
- Lopez G, Eng C, Overman M, Ramirez DL, Liu W, Beinhorn C, Sumler P, Prinsiloo S, Chen M, Li Y, Bruera E, Cohen L. A Pilot Study of Oncology Massage to treat Chemotherapy-Induced Peripheral Neuropathy (CIPN). 2019 Supportive Care in Oncology Symposium 37(15), 2019. PMID: None.
- Lim B, Seth S, Huo L, Layman R, Valero V, Thompson A, White J, Litton J, Damodaran S, Candelaria R, Arun B, Rauch G, Murthy R, Zhao L, Zhang J, Ding Q, Symmans SW, Ramirez D, Ibrahim N, Thomas P, Moulder S, Ueno NT. Comprehensive Profiling of Androgen Receptor-Positive (AR+) Triple-Negative Breast Cancer (TNBC) Patients Treated with Standard Neoadjuvant Therapy (NAT)+/-Enzalutamide. 2020 ASCO. PMID: None.
- Damodaran S, Lu D, Schwartz-Gomer J, Valero V, Ramirez D, Saleem S, Ueno NT, Ibrahim NK, Karuturi M, Murthy RK, Moulder SL, Litton JK. A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2022. PMID: None.
- Farmer LL, Terrell JA, Ramirez DL. Timeliness of care for breast cancer patients with a single day multidisciplinary clinic. 2023 ASCO Annual Meeting 41(16). PMID: None.
- Corredor J, Cordero-Hernandez I, Ramirez DL, Arun B. Development of provider ordered genetic testing pathway and electronic medical record best practice advisory (BPA) to aid in germline genetic testing for patients with metastatic breast cancer. 2023 ASCO Quality Care Symposium 19(11). PMID: None.
Book Chapters
- Ramirez DL, Hughes C, Eid A. Oncology Fourth Addition. In: Approach to Internal Medicine. None. Springer, 203-257, 2015.
Patient Reviews
CV information above last modified October 11, 2024